Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Biologics CDMO Market Set To Climb From $27.55 Billion In 2026 To $48.06 Billion By 2030
The biologics cdmo market size has seen rapid growth in recent years. It is forecast to expand from $24.15 billion in 2025 to $27.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.1%. The expansion observed historically is attributable to a rise in biologics research, progress in cell culture technologies, the increasing occurrence of chronic diseases, the development of biosimilar pipelines, and government assistance for biopharma manufacturing.
The biologics CDMO market is projected to experience swift expansion in the coming years. This market is set to reach $48.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.9%. Factors contributing to this growth during the projected timeframe include a significant increase in gene and cell therapy development, the integration of automation and robotics into CDMO operations, an expansion of worldwide biologics manufacturing capabilities, growing investment in precision medicine, and an increasing need for economical biologics. Key trends anticipated within this period encompass the broadening of biologics CDMO service offerings, an uptick in mammalian cell-based production, greater outsourcing of gene therapy manufacturing, the implementation of sophisticated bioprocessing methods, and a growing demand for biosimilars.
Get A Free Sample Report With In-Depth Market Insights:
Biologics CDMO Market Demand Drivers Opening New Revenue Streams
The increasing need for cell and genetic therapy is projected to drive the expansion of the biologic CDMO market. Cell and gene therapy represent advanced medical strategies that utilize living cells or genetic material to address the fundamental causes of diseases at the cellular or genetic level, providing potential remedies for conditions that are hard to manage or incurable through traditional pharmaceuticals. The demand for these therapies is on the rise due to their potential to offer novel treatments by directly targeting underlying genetic or cellular issues. Biologic CDMOs contribute expertise in handling living cells, viral vectors, and genetic materials, ensuring the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating their progression from research to clinical application. For instance, in March 2024, IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, reported that global spending on cell and gene therapies soared to $5.9 billion in 2023, representing a 38% increase from 2022. Therefore, the significant surge in demand for cell and genetic therapy is propelling the growth of the biologic CDMO market.
Biologics CDMO Market Segment Breakdown: Which Categories Lead On Revenue?
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services
Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
Biologics CDMO Market Trends Powering Strategic Industry Growth
Leading companies in the biologics CDMO market are advancing technologically sophisticated solutions, such as novel cell lines, to boost the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology generates therapeutic antibodies with enhanced potency, addressing obstacles in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing firm specializing in the pharmaceutical and biotechnology sectors, unveiled its GS Effex cell lines. These are engineered to produce antibodies that are 100% free of fucose, a sugar molecule, and exhibit increased potency without sacrificing other performance attributes. This development aids in overcoming immunotherapy research and development challenges tied to the requirement for more potent antibody therapeutics. It represents a stable, scalable, and productive cell line, offering a solution for therapeutic development from the discovery phase all the way through commercial manufacturing.
Biologics CDMO Market Leading Players And Competitive Positioning
Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics
View The Full Biologics CDMO Market Report:
Biologics CDMO Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model